JPRN-UMIN000015404已完成未知
The prospective study of the clinical efficacy/adverse event of regorafenib in unresectable metastatic and advanced colorectal cancer - Prediction of the Efficacy/Adverse event of Regorafenib in advanced Colorectal cancer (PEARC study)
Department of Clinical Oncology, Akita University Hospital0 个研究点目标入组 50 人开始时间: 2014年10月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1. with potent drug affected activity of CYP3A4 or UGT1A9, and with potent drug affected blood concentration of regorafenib. 2. Pregnant female, possibly pregnant females and females feeding babies. 3. with uncontrollable hypertension (systolic >150 mmHg or diastolic >90 mmHg even with hypotensives) 4. with a history of embolism, ischemic heart disease, unstable angina, heart failure or cerebrovascular disease. 5. with severe allergy. 6. Any other patients whom the physician in charge of the study judges to be unsuitable.
研究者
相似试验
招募中
不适用
Clinical prospective study to investigate efficacy and safety of immune-cell therapy for malignant tumorsMalignant tumorJPRN-UMIN000004610Kanazawa university600
已完成
不适用
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.JPRN-UMIN000008046Seta Clinic Group20
已完成
不适用
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapyMalignant tumor (all HLA types)JPRN-UMIN000009447Seta Clinic Group5
招募中
不适用
Prospective study for clinical effectiveness and safety of TAZ/PIPC for the prevention of infectious complication of high risk lung cancer surgeryMalignant lung tumorJPRN-UMIN000003532Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University50
招募中
不适用
A prospective study to evaluate the clinical utility of liquid biopsy in cancer patients underwent tissue based comprehensive genome profiling.solid tumorJPRN-UMIN000041722ational cancer center130
